Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Thiogenesis Therapeutics Corp ( (TSE:TTI) ) has issued an announcement.
Thiogenesis Therapeutics Corp has announced the extension of its investor relations agreement with Triomphe Holdings Ltd., operating as Capital Analytica, for an additional three months ending December 31, 2025. This extension, which involves a monthly payment of $5,000 to the consultant, aims to enhance the company’s investor relations through social media consultation and engagement services. The extension is subject to acceptance by the TSX Venture Exchange, and no securities are being issued as part of this agreement.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is a clinical-stage biopharmaceutical company based in San Diego, California. It is publicly traded on the TSX Venture Exchange and the OTCQX in the U.S. The company focuses on developing sulfur-containing prodrugs that serve as precursors to thiol-active compounds, targeting serious pediatric diseases with unmet medical needs. Its lead product candidate, TTI-0102, is undergoing a Phase 2 clinical trial for MELAS and has a cleared IND for a Phase 2a trial in Leigh syndrome spectrum, with plans for a Phase 2 trial in pediatric MASH.
Average Trading Volume: 28,036
Technical Sentiment Signal: Buy
Current Market Cap: C$38.36M
For detailed information about TTI stock, go to TipRanks’ Stock Analysis page.